{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T02:28:13Z","timestamp":1785637693600,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05902-7","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T12:06:23Z","timestamp":1748952383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis\/multiple Sclerosis-like syndrome: a systematic review"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-0129","authenticated-orcid":false,"given":"Nikolaos","family":"Chaitidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6761-5673","authenticated-orcid":false,"given":"Grigorios T.","family":"Sakellariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0176-6804","authenticated-orcid":false,"given":"Maria","family":"Daviti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2822-2872","authenticated-orcid":false,"given":"Stavritsa Taxiarchoula","family":"Varvara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8968-1080","authenticated-orcid":false,"given":"Michail","family":"Panagiotidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4018-8784","authenticated-orcid":false,"given":"Michael","family":"Arabatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2331-8981","authenticated-orcid":false,"given":"Dimitra","family":"Kiritsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8814-3561","authenticated-orcid":false,"given":"Efstratios","family":"Vakirlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-4718","authenticated-orcid":false,"given":"Elena","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"5902_CR1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/ana.26672","volume":"94","author":"MT Patrick","year":"2023","unstructured":"Patrick MT, Nair RP, He K et al (2023) Shared genetic risk factors for multiple sclerosis\/psoriasis suggest involvement of Interleukin-17 and Janus Kinase-Signal transducers and activators of transcription signaling. Ann Neurol 94:384\u2013397. https:\/\/doi.org\/10.1002\/ana.26672","journal-title":"Ann Neurol"},{"key":"5902_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/ane.12308","volume":"131","author":"G Deretzi","year":"2015","unstructured":"Deretzi G, Kountouras J, Polyzos SA et al (2015) Polyautoimmunity in a Greek cohort of multiple sclerosis. Acta Neurol Scand 131:225\u2013230. https:\/\/doi.org\/10.1111\/ane.12308","journal-title":"Acta Neurol Scand"},{"key":"5902_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.msard.2017.02.012","volume":"13","author":"RA Marrie","year":"2017","unstructured":"Marrie RA, Patten SB, Tremlett H et al (2017) Increased incidence and prevalence of psoriasis in multiple sclerosis. Mult Scler Relat Disord 13:81\u201386. https:\/\/doi.org\/10.1016\/j.msard.2017.02.012","journal-title":"Mult Scler Relat Disord"},{"key":"5902_CR4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/rheumatology\/keu382","volume":"54","author":"DTSL Jansen","year":"2015","unstructured":"Jansen DTSL, Hameetman M, van Bergen J et al (2015) IL-17-producing CD4\u2009+\u2009T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology (Oxford) 54:728\u2013735. https:\/\/doi.org\/10.1093\/rheumatology\/keu382","journal-title":"Rheumatology (Oxford)"},{"key":"5902_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"E Suzuki","year":"2014","unstructured":"Suzuki E, Mellins ED, Gershwin ME et al (2014) The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev 13:496\u2013502. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.050","journal-title":"Autoimmun Rev"},{"key":"5902_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/jid.2009.59","volume":"129","author":"A Di Cesare","year":"2009","unstructured":"Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23\/Th17 axis in the Immunopathogenesis of psoriasis. J Invest Dermatol 129:1339\u20131350. https:\/\/doi.org\/10.1038\/jid.2009.59","journal-title":"J Invest Dermatol"},{"key":"5902_CR7","unstructured":"Cosentyx\u00ae (secukinumab) (2015) [package insert]. Food and drug administration. Novartis Pharmaceuticals Corporation. East Hanover, New Jersey"},{"key":"5902_CR8","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/bjd\/ljae181","volume":"191","author":"T Passeron","year":"2024","unstructured":"Passeron T, Reinhardt M, Ehst B et al (2024) Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study. Br J Dermatol 191:680\u2013690. https:\/\/doi.org\/10.1093\/bjd\/ljae181","journal-title":"Br J Dermatol"},{"key":"5902_CR9","doi-asserted-by":"crossref","unstructured":"Funabiki M, Tahara M, Kondo S et al (2023) SAPHO syndrome complicated by lesions of the central nervous system successfully treated with brodalumab. Case Rep. Rheumatol. 2023:6005531","DOI":"10.1155\/2023\/6005531"},{"key":"5902_CR10","doi-asserted-by":"publisher","unstructured":"Scrivo R, Picchianti-Diamanti A, Chimenti MS et al (2022) Secukinumab treatment in patients with spondyloarthritis and concomitant demyelinating disease: rationale of IL-17 Inhibition and clinical outcome. Arch Clin Med Case Rep 06. https:\/\/doi.org\/10.26502\/acmcr.96550540","DOI":"10.26502\/acmcr.96550540"},{"key":"5902_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2217\/imt-2021-0128","volume":"14","author":"MA Eksin","year":"2022","unstructured":"Eksin MA, Erden A, G\u00fcven SC et al (2022) Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review. Immunotherapy 14:401\u2013408. https:\/\/doi.org\/10.2217\/imt-2021-0128","journal-title":"Immunotherapy"},{"key":"5902_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","volume":"263","author":"E Havrdov\u00e1","year":"2016","unstructured":"Havrdov\u00e1 E, Belova A, Goloborodko A et al (2016) Activity of Secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol 263:1287\u20131295. https:\/\/doi.org\/10.1007\/s00415-016-8128-x","journal-title":"J Neurol"},{"key":"5902_CR13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/1346-8138.17143","volume":"51","author":"SG Tsiogkas","year":"2024","unstructured":"Tsiogkas SG, Tsimourtou V, Chaidaki K et al (2024) Risk of multiple sclerosis in patients with psoriasis receiving anti-IL-17 agents: A case-based review. J Dermatol 51:844\u2013848. https:\/\/doi.org\/10.1111\/1346-8138.17143","journal-title":"J Dermatol"},{"key":"5902_CR14","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647","journal-title":"BMJ"},{"key":"5902_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ evidence-based Med 23:60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ evidence-based Med"},{"key":"5902_CR16","unstructured":"IBM Corp Released 2022. IBM SPSS statistics for windows, version 29.0.2.0 Armonk, NY: IBM Corp"},{"key":"5902_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1684\/ejd.2016.2832","volume":"26","author":"T Komori","year":"2016","unstructured":"Komori T, Otsuka A, Honda Y et al (2016) Exacerbation of depression in a psoriatic arthritis patient possibly induced by Secukinumab. Eur J Dermatol 26:506\u2013507. https:\/\/doi.org\/10.1684\/ejd.2016.2832","journal-title":"Eur J Dermatol"},{"key":"5902_CR18","doi-asserted-by":"publisher","unstructured":"Jartych A, Jamroz A, Rejdak K et al (2024) A case of concomitant juvenile idiopathic arthritis (JIA) and paediatric-onset multiple sclerosis (POMS)\u2013 treatment with Secukinumab and dimethyl fumarate followed by ofatumumab. J Pre-Clinical Clin Res 1. https:\/\/doi.org\/10.26444\/jpccr\/185685","DOI":"10.26444\/jpccr\/185685"},{"key":"5902_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.18295\/squmj.4.2021.021","volume":"21","author":"E Herrera-Acosta","year":"2021","unstructured":"Herrera-Acosta E, Garriga-Martina GG, Su\u00e1rez-P\u00e9rez JA et al (2021) Ixekizumab for patients with plaque psoriasis affected by multiple sclerosis: case report. Sultan Qaboos Univ Med J 21:488\u2013490","journal-title":"Sultan Qaboos Univ Med J"},{"key":"5902_CR20","doi-asserted-by":"crossref","unstructured":"Gerhardt M, Bonato G, dos Passos G, Becker J (2024) Combination of Secukinumab and natalizumab in the treatment of a patient with psoriatic arthritis and multiple sclerosis. In: Arquivos de Neuro-Psiquiatria","DOI":"10.1055\/s-0044-1789394"},{"key":"5902_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.24911\/ejmcr\/173-1642670323","volume":"6","author":"Z Estere","year":"2022","unstructured":"Estere Z, Meksa L, Kadisa A et al (2022) Concomitant multiple sclerosis and ankylosing spondylitis: a clinical case report. Eur J Med Case Rep 6:95\u2013101. https:\/\/doi.org\/10.24911\/ejmcr\/173-1642670323","journal-title":"Eur J Med Case Rep"},{"key":"5902_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.msard.2019.03.009","volume":"31","author":"M Diebold","year":"2019","unstructured":"Diebold M, M\u00fcller S, Derfuss T, D\u00e9card BF (2019) A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions. Mult Scler Relat Disord 31:38\u201340. https:\/\/doi.org\/10.1016\/j.msard.2019.03.009","journal-title":"Mult Scler Relat Disord"},{"key":"5902_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.msard.2019.08.006","volume":"35","author":"A Cortese","year":"2019","unstructured":"Cortese A, Lucchetti R, Altobelli A et al (2019) Secukinumab May be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: report of two clinical cases. Mult Scler Relat Disord 35:193\u2013195. https:\/\/doi.org\/10.1016\/j.msard.2019.08.006","journal-title":"Mult Scler Relat Disord"},{"key":"5902_CR24","doi-asserted-by":"crossref","unstructured":"Cavaglieri LP, Boaventura M (2023) The association of Secukinumab and ofatumumab. concomitant ankylosing spondylitis and multiple sclerosis","DOI":"10.17648\/bctrims-2023-167482"},{"key":"5902_CR25","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/1346-8138.14619","volume":"46","author":"GT Assefa","year":"2019","unstructured":"Assefa GT, Kaneko S, Oguro H, Morita E (2019) Treatment of psoriasis and psoriatic arthritis with Secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient. J Dermatol 46:e112\u2013e113","journal-title":"J Dermatol"},{"key":"5902_CR26","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1111\/jdv.16035","volume":"34","author":"M Venturini","year":"2020","unstructured":"Venturini M, Zanca A, Venturuzzo A et al (2020) Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report. J Eur Acad Dermatol Venereol 34:e110\u2013e112","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5902_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.biologicals.2019.06.002","volume":"60","author":"MK Nisar","year":"2019","unstructured":"Nisar MK (2019) Combining Secukinumab and Fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis\u2013 A novel approach. Biologicals 60:93\u201394. https:\/\/doi.org\/10.1016\/j.biologicals.2019.06.002","journal-title":"Biologicals"},{"key":"5902_CR28","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1111\/ajd.13983","volume":"64","author":"M Megna","year":"2023","unstructured":"Megna M, Noto M, Fabbrocini G, Fornaro L (2023) A case of psoriasis and multiple sclerosis succesfully treated with concomitant Fingolimod and Secukinumab. Australas J Dermatol 64:e100\u2013e102","journal-title":"Australas J Dermatol"},{"key":"5902_CR29","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1111\/ijd.14902","volume":"59","author":"M Megna","year":"2020","unstructured":"Megna M, Marasca C, Ruggiero A et al (2020) Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis? Int J Dermatol 59:e308\u2013e309","journal-title":"Int J Dermatol"},{"key":"5902_CR30","doi-asserted-by":"publisher","first-page":"111211","DOI":"10.1016\/j.jocn.2025.111211","volume":"136","author":"E Madill","year":"2025","unstructured":"Madill E, Galetta K, Opeyemi O et al (2025) Safety and efficacy of anti-IL-17A use in multiple sclerosis and comorbid rheumatological disease: A multi-center exploratory study. J Clin Neurosci Off J Neurosurg Soc Australas 136:111211. https:\/\/doi.org\/10.1016\/j.jocn.2025.111211","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"5902_CR31","first-page":"1096","volume":"37","author":"F Macaluso","year":"2019","unstructured":"Macaluso F, Guggino G, Mauro D et al (2019) Safety and efficacy of Secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis. Clin Exp Rheumatol 37:1096","journal-title":"Clin Exp Rheumatol"},{"key":"5902_CR32","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.nerep.2022.100054","volume":"2","author":"N Kougkas","year":"2022","unstructured":"Kougkas N, Kruger-Krasagakis S, Papadaki E, Mastorodemos V (2022) Successful treatment of highly active multiple sclerosis and psoriasis exacerbation with natalizumab and Secukinumab combination. A case report and literature review. Neuroimmunol Rep 2:100054. https:\/\/doi.org\/10.1016\/j.nerep.2022.100054","journal-title":"Neuroimmunol Rep"},{"key":"5902_CR33","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10494","author":"V Furer","year":"2023","unstructured":"Furer V, Elkayam O (2023) Dual biologic therapy in patients with rheumatoid arthritis and psoriatic arthritis. Rambam Maimonides Med J. https:\/\/doi.org\/10.5041\/RMMJ.10494. 14:","journal-title":"Rambam Maimonides Med J"},{"key":"5902_CR34","doi-asserted-by":"publisher","first-page":"175628482413098","DOI":"10.1177\/17562848241309871","volume":"18","author":"A Fabisiak","year":"2025","unstructured":"Fabisiak A, Caban M, Dudek P et al (2025) Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions. Th Adv Gastroenterol 18:17562848241309872. https:\/\/doi.org\/10.1177\/17562848241309871","journal-title":"Th Adv Gastroenterol"},{"key":"5902_CR35","doi-asserted-by":"publisher","first-page":"103331","DOI":"10.1016\/j.jaut.2024.103331","volume":"149","author":"V Solitano","year":"2024","unstructured":"Solitano V, Yuan Y, Singh S et al (2024) Efficacy and safety of advanced combination treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials. J Autoimmun 149:103331. https:\/\/doi.org\/10.1016\/j.jaut.2024.103331","journal-title":"J Autoimmun"},{"key":"5902_CR36","doi-asserted-by":"publisher","unstructured":"Yashima K, Kurumi H, Yamaguchi N, Isomoto H (2025) Progressing advanced therapies for inflammatory bowel disease: current status including dual biologic therapy and discontinuation of biologics. Expert Rev Gastroenterol Hepatol 1\u201320. https:\/\/doi.org\/10.1080\/17474124.2025.2469832","DOI":"10.1080\/17474124.2025.2469832"},{"key":"5902_CR37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/annrheumdis-2020-218019","volume":"79","author":"JD Isaacs","year":"2020","unstructured":"Isaacs JD, Burmester GR (2020) Smart battles: immunosuppression versus Immunomodulation in the inflammatory RMDs. Ann Rheum Dis 79:991\u2013993","journal-title":"Ann Rheum Dis"},{"key":"5902_CR38","doi-asserted-by":"publisher","first-page":"30201","DOI":"10.11613\/BM.2017.030201","volume":"27","author":"A Mlinari\u0107","year":"2017","unstructured":"Mlinari\u0107 A, Horvat M, \u0160upak Smol\u010di\u0107 V (2017) Dealing with the positive publication bias: why you should really publish your negative results. Biochem Med 27:30201. https:\/\/doi.org\/10.11613\/BM.2017.030201","journal-title":"Biochem Med"},{"key":"5902_CR39","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/ncpneuro0618","volume":"3","author":"RT Johnson","year":"2007","unstructured":"Johnson RT, Dickersin K (2007) Publication bias against negative results from clinical trials: three of the seven deadly sins. Nat Clin Pract Neurol 3:590\u2013591. https:\/\/doi.org\/10.1038\/ncpneuro0618","journal-title":"Nat Clin Pract Neurol"},{"key":"5902_CR40","doi-asserted-by":"publisher","first-page":"566","DOI":"10.4049\/jimmunol.177.1.566","volume":"177","author":"Y Komiyama","year":"2006","unstructured":"Komiyama Y, Nakae S, Matsuki T et al (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177:566\u2013573. https:\/\/doi.org\/10.4049\/jimmunol.177.1.566","journal-title":"J Immunol"},{"key":"5902_CR41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","volume":"172","author":"JS Tzartos","year":"2008","unstructured":"Tzartos JS, Friese MA, Craner MJ et al (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172:146\u2013155. https:\/\/doi.org\/10.2353\/ajpath.2008.070690","journal-title":"Am J Pathol"},{"key":"5902_CR42","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS et al (2019) 2019 Update of the American college of rheumatology\/spondylitis association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol (Hoboken NJ) 71:1599\u20131613. https:\/\/doi.org\/10.1002\/art.41042","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"5902_CR43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A et al (2019) Special Article: 2018 American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken) 71:2\u201329. https:\/\/doi.org\/10.1002\/acr.23789","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5902_CR44","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N et al (2022) Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18:465\u2013479. https:\/\/doi.org\/10.1038\/s41584-022-00798-0","journal-title":"Nat Rev Rheumatol"},{"key":"5902_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A et al (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82:19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"key":"5902_CR46","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO et al (2024) EULAR recommendations for the management of psoriatic arthritis with Pharmacological therapies: 2023 update. Ann Rheum Dis 83:706\u2013719. https:\/\/doi.org\/10.1136\/ard-2024-225531","journal-title":"Ann Rheum Dis"},{"key":"5902_CR47","unstructured":"Nast A, Spuls PI, Dressler C et al (2023) EuroGuiDerm guideline for the systemic treatment of psoriasis vulgaris"},{"key":"5902_CR48","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1212\/WNL.0000000000201472","volume":"100","author":"L Li","year":"2023","unstructured":"Li L, Avi\u00f1a-Zubieta JA, Bernstein CN et al (2023) Risk of multiple sclerosis among users of antitumor necrosis factor \u03b1 in 4 Canadian provinces: A Population-Based study. Neurology 100:e558\u2013e567. https:\/\/doi.org\/10.1212\/WNL.0000000000201472","journal-title":"Neurology"},{"key":"5902_CR49","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s00296-021-04995-0","volume":"41","author":"M Bare\u0161i\u0107","year":"2021","unstructured":"Bare\u0161i\u0107 M, Reihl Crnogaj M, Zadro I, Ani\u0107 B (2021) Demyelinating disease (multiple sclerosis) in a patient with psoriatic arthritis treated with adalimumab: a case-based review. Rheumatol Int 41:2233\u20132239. https:\/\/doi.org\/10.1007\/s00296-021-04995-0","journal-title":"Rheumatol Int"},{"key":"5902_CR50","doi-asserted-by":"crossref","unstructured":"Chang S, Chambers CJ, Liu F-T, Armstrong AW (2015) Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis. Dermatol Online J 21","DOI":"10.5070\/D3217028112"},{"key":"5902_CR51","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","volume":"7","author":"BM Segal","year":"2008","unstructured":"Segal BM, Constantinescu CS, Raychaudhuri A et al (2008) Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, Ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7:796\u2013804. https:\/\/doi.org\/10.1016\/S1474-4422(08)70173-X","journal-title":"Lancet Neurol"},{"key":"5902_CR52","doi-asserted-by":"publisher","unstructured":"Sakellariou GT, Chaitidis N, Katsigianni I et al (2025) A patient with multiple sclerosis successfully treated with Tofacitinib for rheumatoid arthritis. Scand J Rheumatol 1\u20133. https:\/\/doi.org\/10.1080\/03009742.2025.2463733","DOI":"10.1080\/03009742.2025.2463733"},{"key":"5902_CR53","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1212\/NXI.0000000000000328","volume":"4","author":"SC Hodecker","year":"2017","unstructured":"Hodecker SC, Stellmann J-P, Rosenkranz SC et al (2017) Ruxolitinib treatment in a patient with neuromyelitis Optica: A case report. Neurol Neuroimmunol Neuroinflammation 4:e328. https:\/\/doi.org\/10.1212\/NXI.0000000000000328","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"5902_CR54","doi-asserted-by":"publisher","first-page":"e15477","DOI":"10.1111\/dth.15477","volume":"35","author":"R Er\u00e7oban","year":"2022","unstructured":"Er\u00e7oban R, \u0130slamo\u011flu ZGK (2022) New developing multiple sclerosis in a patient using Tofacitinib due to alopesia areata. Dermatol Ther 35:e15477","journal-title":"Dermatol Ther"},{"key":"5902_CR55","doi-asserted-by":"publisher","first-page":"102568","DOI":"10.1016\/j.msard.2020.102568","volume":"46","author":"F Massoud","year":"2020","unstructured":"Massoud F, Ismail II, Al-Hashel JY, Abboud H (2020) CNS demyelination during Tofacitinib therapy: first report. Mult Scler Relat Disord 46:102568","journal-title":"Mult Scler Relat Disord"},{"key":"5902_CR56","doi-asserted-by":"publisher","first-page":"e15137","DOI":"10.1111\/1756-185X.15137","volume":"27","author":"Y Yang","year":"2024","unstructured":"Yang Y, Zhou W (2024) Case report: Tofacitinib alleviates psoriatic arthritis without exacerbating multiple sclerosis. Int J Rheum Dis 27:e15137","journal-title":"Int J Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05902-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05902-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05902-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T09:30:41Z","timestamp":1750239041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05902-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["5902"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05902-7","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare that no part of this manuscript, including the text and graphics, has been copied or published elsewhere, either in whole or in part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior publication"}},{"value":"We confirm that we have no conflicts of interest to declare, including no relationships with pharmaceutical companies promoting IL-17 inhibitors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"147"}}